Your browser doesn't support javascript.
loading
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi, Masakazu; Imoto, Shigeru; Ishida, Takanori; Ito, Yoshinori; Iwata, Hiroji; Masuda, Norikazu; Mukai, Hirofumi; Saji, Shigehira; Shimizu, Akira; Ikeda, Takafumi; Haga, Hironori; Saeki, Toshiaki; Aogi, Kenjiro; Sugie, Tomoharu; Ueno, Takayuki; Kinoshita, Takayuki; Kai, Yuichiro; Kitada, Masahiro; Sato, Yasuyuki; Jimbo, Kenjiro; Sato, Nobuaki; Ishiguro, Hiroshi; Takada, Masahiro; Ohashi, Yasuo; Ohno, Shinji.
Afiliação
  • Toi M; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan. Electronic address: toi@kuhp.kyoto-u.ac.jp.
  • Imoto S; Kyorin University Hospital, Mitaka, Japan.
  • Ishida T; Tohoku University, Sendai, Japan.
  • Ito Y; Cancer Institute Hospital, Tokyo, Japan.
  • Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan.
  • Masuda N; National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Mukai H; National Cancer Center Hospital East, Kashiwa, Japan.
  • Saji S; Fukushima Medical University, Fukushima, Japan.
  • Shimizu A; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
  • Ikeda T; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
  • Haga H; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
  • Saeki T; Saitama Medical University International Medical Center, Hidaka, Japan.
  • Aogi K; National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Sugie T; Kansai Medical University Hospital, Hirakata, Japan.
  • Ueno T; Cancer Institute Hospital, Tokyo, Japan.
  • Kinoshita T; National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kai Y; Ueo Breast Surgery Clinic, Oita, Japan.
  • Kitada M; Asahikawa Medical University Hospital, Asahikawa, Japan.
  • Sato Y; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Jimbo K; National Cancer Center Hospital, Tokyo, Japan.
  • Sato N; Niigata Cancer Center Hospital, Niigata, Japan.
  • Ishiguro H; International University of Health and Welfare Narita Hospital, Narita, Japan.
  • Takada M; Breast Cancer Unit, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan.
  • Ohashi Y; Chuo University, Tokyo, Japan.
  • Ohno S; Cancer Institute Hospital, Tokyo, Japan.
Lancet Oncol ; 22(1): 74-84, 2021 01.
Article em En | MEDLINE | ID: mdl-33387497
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrogênio / Biomarcadores Tumorais / Tegafur / Receptor ErbB-2 / Moduladores Seletivos de Receptor Estrogênico / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrogênio / Biomarcadores Tumorais / Tegafur / Receptor ErbB-2 / Moduladores Seletivos de Receptor Estrogênico / Inibidores da Aromatase Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article